The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells

Cancer Research

Volumn 63, Issue 19, 2003, Pages 6506-6515

  Mandic, Maja ^a   Almunia, Christine ^b   Vicel, Stephanie ^b   Gillet, Daniel ^b   Janjic, Bratislav ^a   Coval, Kara ^a   Maillere, Bernard ^b   Kirkwood, John M ^a   Zarour, Hassane M ^a,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b CEA SACLAY   (France)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; EPITOPE; GENE PRODUCT; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

AMINO ACID SEQUENCE; ARTICLE; CELL STIMULATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOREACTIVITY; LAGE 1 GENE; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; NUCLEOTIDE SEQUENCE; NY ESO 1 GENE; ONCOGENE; OPEN READING FRAME; PLACENTA; PRIORITY JOURNAL; TESTIS; TH1 CELL;

AMINO ACID SEQUENCE; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; BINDING SITES; CELL LINE, TUMOR; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; HLA-DR ANTIGENS; HUMANS; MELANOMA; MEMBRANE PROTEINS; MOLECULAR SEQUENCE DATA; OPEN READING FRAMES; PROTEINS; TH1 CELLS;

EID: 0141988672     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Chen, Y. T., Scanlan, M. J., Sahin, U., Tureci, O., Gure, A. O., Tsang, S., Williamson, B., Stockert, E., Pfreundschuh, M., and Old, L. J. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA, 94: 1914-1918, 1997.
2. Jager, E., Chen, Y. T., Drijfhout, J. W., Karbach, J., Ringhoffer, M., Jager, D., Arand, M., Wada, H., Noguchi, Y., Stockert, E., Old, L. J., and Knuth, A. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med., 187: 265-270, 1998.
3. Zeng, G., Wang, X., Robbins, P. F., Rosenberg, S. A., and Wang, R. F. CD4+ T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: Association with NY-ESO-1 antibody production. Proc. Natl. Acad. Sci. USA, 98: 3964-3969, 2001.
4. Schultz, E. S., Lethe, B., Cambiaso, C. L., Van Snick, J., Chaux, P., Corthals, J., Heirman, C., Thielemans, K., Boon, T., and van der Bruggen, P. A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes. Cancer Res., 60: 6272-6275, 2000.
5. Uyttenhove, C., Godfraind, C., Lethe, B., Amar-Costesec, A., Renauld, J. C., Gajewski, T. F., Duffour, M. T., Warnier, G., Boon, T., and Van den Eynde, B. J. The expression of mouse gene P1A in testis does not prevent safe induction of cytolytic T cells against a P1A-encoded tumor antigen. Int. J. Cancer, 70: 349-356, 1997.
6. Stockert, E., Jager, E., Chen, Y. T., Scanlan, M. J., Gout, I., Karbach, J., Arand, M., Knuth, A., and Old, L. J. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens [see comments]. J. Exp. Med., 187: 1349-1354, 1998.
7. Jager, E., Nagata, Y., Gnjatic, S., Wada, H., Stockert, E., Karbach, J., Dunbar, P. R., Lee, S. Y., Jungbluth, A., Jager, D., Arand, M., Ritter, G., Cerundolo, V., Dupont, B., Chen, Y. T., Old, L. J., and Knuth, A. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc. Natl. Acad. Sci. USA, 97: 4760-4765, 2000.
8. Jager, E., Gnjatic, S., Nagata, Y., Stockert, E., Jager, D., Karbach, J., Neumann, A., Rieckenberg, J., Chen, Y. T., Ritter, G., Hoffman, E., Arand, M., Old, L. J., and Knuth, A. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc. Natl. Acad. Sci. USA, 97: 12198-203, 2000.
9. Wang, R. F., Johnston, S. L., Zeng, G., Topalian, S. L., Schwartzentruber, D. J., and Rosenberg, S. A. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J. Immunol., 161: 3598-606, 1998.
10. Gnjatic, S., Nagata, Y., Jager, E., Stockert, E., Shankara, S., Roberts, B. L., Mazzara, G. P., Lee, S. Y., Dunbar, P. R., Dupont, B., Cerundolo, V., Ritter, G., Chen, Y. T., Knuth, A., and Old, L. J. Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proc. Natl. Acad. Sci. USA, 97: 10917-22, 2000.
11. Jager, E., Jager, D., Karbach, J., Chen, Y. T., Ritter, G., Nagata, Y., Gnjatic, S., Stockert, E., Arand, M., Old, L. J., and Knuth, A. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. J. Exp. Med., 191: 625-630, 2000.
12. Zeng, G., Touloukian, C. E., Wang, X., Restifo, N. P., Rosenberg, S. A., and Wang, R. F. Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J. Immunol., 165: 1153-1159, 2000.
13. Zarour, H. M., Storkus, W. J., Brusic, V., Williams, E., and Kirkwood, J. M. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. Cancer Res., 60: 4946-4952, 2000.
14. Zarour, H. M., Maillere, B., Brusic, V., Coval, K., Williams, E., Pouvelle-Moratille, S., Castelli, F., Land, S., Bennouna, J., Logan, T., and Kirkwood, J. M. NY-ESO-1 119-143 Is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. Cancer Res., 62: 213-218, 2002.
15. Aarnoudse, C. A., van den Doel, P. B., Heemskerk, B., and Schrier, P. I. Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1. Int. J. Cancer, 82: 442-448, 1999.
16. Rimoldi, D., Rubio-Godoy, V., Dutoit, V., Lienard, D., Salvi, S., Guillaume, P., Speiser, D., Stockert, E., Spagnoli, G., Servis, C., Cerottini, J. C., Lejeune, F., Romero, P., and Valmori, D. Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma. J. Immunol., 165: 7253-7261, 2000.
17. Slager, E. H., Borghi, M., Van Der Minne, C. E., Aarnoudse, C. A., Havenga, M. J., Schrier, P. I., Osanto, S., and Griffioen, M. CD4(+) Th2 cell recognition of HLA-DR-restricted epitopes derived from CAMEL: a tumor antigen translated in an alternative open reading frame. J. Immunol., 170: 1490-1497, 2003.
18. Turvy, D. N., and Blum, J. S. Detection of biotinylated cell surface receptors and MHC molecules in a capture ELISA: a rapid assay to measure endocytosis. J. Immunol. Methods, 212: 9-18, 1998.
19. Texier, C., Pouvelle, S., Busson, M., Herve, M., Charron, D., Menez, A., and Maillere, B. HLA-DR restricted peptide candidates for bee venom immunotherapy. J. Immunol., 164: 3177-3184, 2000.
20. Thannhauser, T. W., Konishi, Y., and Scheraga, H. A. Sensitive quantitative analysis of disulfide bonds in polypeptides and proteins. Anal. Biochem., 138: 181-188, 1984.
21. Texier, C., Pouvelle-Moratille, S., Busson, M., Charron, D., Menez, A., and Maillere, B. Complementarity and redundancy of the binding specificity of HLA-DRB1, -DRB3, -DRB4 and -DRB5 molecules. Eur. J. Immunol., 31: 1837-1846, 2001.
22. Zarour, H. M., Kirkwood, J. M., Kierstead, L. S., Herr, W., Brusic, V., Slingluff, C. L., Jr., Sidney, J., Sette, A., and Storkus, W. J. Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Proc. Natl. Acad. Sci. USA, 97: 400-405, 2000.
23. Herr, W., Schneider, J., Lohse, A. W., Meyer zum Buschenfelde, K. H., and Wolfel, T. Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor a in response to HLA-A2.1-binding melanoma and viral peptide antigens. J. Immunol. Methods, 191: 131-142, 1996.
24. Sturniolo, T., Bono, E., Ding, J., Raddrizzani, L., Tuereci, O., Sahin, U., Braxenthaler, M., Gallazzi, F., Protti, M. P., Sinigaglia, F., and Hammer, J. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat. Biotechnol., 17: 555-561, 1999.
25. Texier, C., Pouvelle-Moratille, S., Buhot, C., Castelli, F. A., Pecquet, C., Menez, A., Leynadier, F., and Maillere, B. Emerging principles for the design of promiscuous HLA-DR-restricted peptides: an example from the major bee venom allergen. Eur. J. Immunol., 32: 3699-707, 2002.
26. Khong, H. T., and Rosenberg, S. A. Pre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy. J. Immunol., 168: 951-956, 2002.
27. Wang, R. F., Parkhurst, M. R., Kawakami, Y., Robbins, P. F., and Rosenberg, S. A. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J. Exp. Med., 183: 1131-1140, 1996.
28. Rosenberg, S. A., Tong-On, P., Li, Y., Riley, J. P., El-Gamil, M., Parkhurst, M. R., and Robbins, P. F. Identification of BING-4 cancer antigen translated from an alternative open reading frame of a gene in the extended MHC class II region using lymphocytes from a patient with a durable complete regression following immunotherapy. J. Immunol., 168: 2402-2407, 2002.
29. Kobayashi, H., Wood, M., Song, Y., Appella, E., and Celis, E. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen. Cancer Res., 60: 5228-5236, 2000.
30. Kobayashi, H., Song, Y., Hoon, D. S., Appella, E., and Celis, E. Tumor-reactive t helper lymphocytes recognize a promiscuous mage-a3 epitope presented by various major histocompatibility complex class ii alleles. Cancer Res., 61: 4773-4778, 2001.
31. Southwood, S., Sidney, J., Kondo, A., del Guercio, M. F., Appella, E., Hoffman, S., Kubo, R. T., Chesnut, R. W., Grey, H. M., and Sette, A. Several common HLA-DR types share largely overlapping peptide binding repertoires. J. Immunol., 160: 3363-3373, 1998.
32. Zeng, G., Li, Y., El-Gamil, M., Sidney, J., Sette, A., Wang, R. F., Rosenberg, S. A., and Robbins, P. F. Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. Cancer Res., 62: 3630-3635, 2002.
33. Cella, M., Scheidegger, D., Palmer-Lehmann, K., Lane, P., Lanzavecchia, A., and Alber, G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation, J. Exp. Med., 184: 747-752, 1996.
34. Lanzavecchia, A., and Sallusto, F. Dynamics of T lymphocyte responses: intermediates, effectors, and memory cells. Science (Wash. DC), 290: 92-97, 2000.
35. Lethe, B., Lucas, S., Michaux, L., De Smet, C., Godelaine, D., Serrano, A., De Plaen, E., and Boon, T. LAGE-1, a new gene with tumor specificity. Int. J. Cancer, 76: 903-908, 1998.